Table 1 Aberrant somatic hypermutation of RHOH in human cancers.

Hodgkin

lymphoma (HL)

Nodular lymphocyte predominant HL (n = 10)

Classic HL (n = 9)

80%

55.5%

11.1%

0%

[51]

Mature B-cell neoplasms

Diffuse large B-cell lymphoma (n = 39)

>50%

46%

[35]

Mature B-cell neoplasms

Nodal marginal zone lymphoma and

Splenic marginal zone lymphoma (n = 55)

13%

Not c-MYC

3.6%

[44]

Mature B-cell neoplasms

Mucosa-associated lymphoid tissue lymphoma (n = 17)

Extranodal diffuse large B-cell lymphoma (n = 17)

76.5%

100%

11.8%

47.1%

[45]

Mature B-cell neoplasms

Primary CNS lymphoma (n = 10)

90%

70%

[46]

Mature B-cell neoplasms

Primary cutaneous large B-cell lymphoma, leg type (n = 13)

Primary cutaneous follicle centre lymphoma (n = 19)

54%

53%

Not PIM1

30.7%

10.5%

[47]

Mature B-cell neoplasms

Follicular lymphoma

Diffuse large B-cell lymphoma (n = 9)

Chronic lymphocytic leukaemia

Diffuse large B-cell lymphoma (n = 9)

33.3%

55.5%

11.1%

22.2%

33%

11.1%

[48]

Mature B-cell neoplasms

Chronic lymphocytic leukaemia (n = 15)

Diffuse large B-cell lymphoma (n = 13)

Prolymphocytic transformation (n = 8)

26.7%

100%

100%

Not PIM1

0%

46.1%

25%

[49]

Mature B-cell neoplasms

Diffuse large B-cell lymphoma (n = 100)

>50%

35%

[50]

Mature B-cell neoplasms

Mediastinal B-cell lymphoma (n = 6)

100%

Not PIM1

66%

[72]

Mature B-cell neoplasms

Low grade follicular lymphoma (n = 32)

Transformed follicular lymphoma (n = 26)

75%

77%

16%

31%

[73]

Immunodeficiency-associated lympho-proliferative disorders

Post-transplant LD (n = 21)

Polymorphic PTLD (n = 8)

Monomorphic PTLD (n = 12)

45%

12.5%

66.7%

20%

20%

40%

[52]

Immunodeficiency-associated lympho-proliferative disorders

AIDS-associated non-Hodgkin lymphoma (n = 39)

48.7%

23.1%

[53]

Immunodeficiency-associated lympho-proliferative disorders

HCV-associated non-Hodgkin lymphoma (n = 9)

31%

13%

[54]